ABC Baseline Physical Exam Form in Efficacy and Impact of Botulinum Toxin A versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence

Patient baseline physical examination findings, SAS
Study Description
Urinary incontinence is a condition that markedly impacts quality of life. Conservative first line treatments for urge incontinence combined with other overactive bladder (OAB) symptoms include behavioral therapy, pelvic floor training +/- biofeedback, or the use of anticholinergic medications. These treatment modalities may not result in total continence and are often not sustained for various reasons. Thus, the objective of the Anticholinergic versus Botox Comparison Study (ABC) was to determine whether a single intra-detrusor injection of botulinum toxin A (Botox A®) is more effective than a standardized regimen of oral anticholinergics in reducing urge urinary incontinence (UUI). Oral anticholinergic therapy and Botox A® by injection were associated with similar reductions in the frequency of daily episodes of UUI. The group receiving Botox A® was less likely to have dry mouth and more likely to have complete resolution of UUI but had higher rates of transient urinary retention and urinary tract infections. Participants were females at least 21 years of age with urge predominant urinary incontinence based on a self-reported diary who desired treatment for urge urinary incontinence.

患者基线体格检查结果（SAS）
研究概况
尿失禁是一种显著影响生活质量的病症。针对合并膀胱过度活动症（Overactive Bladder，OAB）症状的急迫性尿失禁，一线保守治疗手段包括行为疗法、盆底肌训练±生物反馈，或使用抗胆碱能药物。上述治疗手段未必能实现完全控尿，且常因多种原因难以持续。因此，抗胆碱能药物与肉毒杆菌毒素对比研究（ABC）的研究目标，旨在明确单次逼尿肌内注射A型肉毒杆菌毒素（Botox A®）是否比标准化口服抗胆碱能药物方案更能降低每日急迫性尿失禁（Urge Urinary Incontinence，UUI）的发作频率。
口服抗胆碱能药物治疗与注射型Botox A®在降低每日UUI发作频率方面效果相近。接受Botox A®注射的受试者出现口干的概率更低，实现UUI完全缓解的比例更高，但一过性尿潴留与尿路感染的发生率更高。本研究的受试者为年龄≥21岁的女性，经自我报告的排尿日记确诊为急迫性为主型尿失禁，且存在急迫性尿失禁治疗需求。